HOME >> MEDICINE >> NEWS
Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis

ORLANDO -- After angioplasty is performed to widen clogged arteries, surgeons frequently use tiny wire-mesh tubes called stents to keep blood vessels open. But despite stenting, scar tissue can form to create new blockages -- a process called in-stent restenosis (ISR). At present, vascular brachytherapy (catheter-based delivery of intracoronary radiation) is the only therapeutic modality proven to effectively reduce in-stent restenosis. But a team of Emory cardiology researchers presented a study at the American College of Cardiology (ACC) Scientific Sessions today showing that patients with ISR treated with a sirolimus-eluting stent (SES), which releases the therapeutic agent sirolimus over time to prevent restenosis, fared at least as well as those treated with vascular brachytherapy (VB). Moreover, the patients who received the drug eluting stent had fewer cardiac events afterwards.

"The efficacy of the SES in native coronary arteries is proven -- but the safety and efficacy of drug eluting stents in the treatment of ISR is unclear. To help clarify these issues, we compared in-hospital and six month outcomes in patients with ISR treated either with SES or vascular brachytherapy (VB)," explains Emory Heart Center interventional cardiologist Peter C. Block, MD, the principal investigator of the study.

Using a retrospective non-randomized study design, the Emory team analyzed the U.S. nationwide post marketing surveillance registry maintained by Cordis (maker of the Cypher SES) which included 2063 patients implanted with Cypher SES between August of 2003 and December of 2003 -- 136 of whom had received SES for ISR.

The Emory researchers also identified 99 patients in the Emory cardiac databank who received VB as treatment of ISR between July of 2003 and January of 2004. These patients were contacted by telephone 4 to 8 months following their VB for a phone interview about their cardiac symptoms and outcomes.

Using t
'"/>

Contact: Sherry Baker
emoryheartnews@aol.com
404-377-1398
Emory University Health Sciences Center
7-Mar-2005


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in national ... Powder Cancer Lawsuit Center website. Just as the previous version did, the new website ... timely lawsuit updates and ovarian cancer warning information. The site is routinely updated with ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... great for documenting memories. , Almost every smartphone has an incredibly powerful camera built ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently running ... to those of celebrities will have the opportunity to get 10% discount on orders ... that people do not have to use coupon codes or remember redemption codes. ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is ... is now the 19th sweetFrog store located in the Lone Star State. The premium ... growing companies in 2014. , The store, which opened July 1 at Duke’s Travel ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... retrofit project at the University of Minnesota, they knew it would save the ... also be an award-winning choice: the total energy savings after installation was an ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2
(Date:7/2/2015)... ATLANTA , July 2, 2015 Legal-Bay ... U.S. District Judge Joseph Goodwin in the ... (VA) consolidated 26 transvaginal mesh cases against Ethicon for ... nd . The cases for the 26 women include ... by a device made my Johnson & Johnson,s Ethicon ...
(Date:7/1/2015)... SCHAUMBURG, Ill. , July 1, 2015 /PRNewswire-USNewswire/ ... a nationwide group of state and regional professional ... national survey of rheumatologists that explored perceptions of ... drugs on patients. Biosimilars are ... to biologic medicines. They are notably different from ...
(Date:7/1/2015)... 1, 2015   Cochlear Limited (ASX: ... announced today the US Food and Drug Administration ... with Slim Straight Electrode (CI522). Built on over ... collaboration with the world,s leading surgeons, the Profile ... to provide the most discreet appearance for both ...
Breaking Medicine Technology:Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 3
Cached News: